Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2011 Sep 21;5(3):50-2.
doi: 10.3315/jdcr.2011.1075.

Progressive symmetrical erythrokeratoderma - response to topical calcipotriol

Ilgül Bilgin  1 , Kübra Eren Bozdağ, Seçil Uysal, Murat Ermete
Affiliations
Case Reports

Progressive symmetrical erythrokeratoderma - response to topical calcipotriol

Ilgül Bilgin et al. J Dermatol Case Rep. .

Abstract

Background: Progressive symmetrical erythrokeratoderma is characterized by well-demarcated, symmetrically distributed, erythtematous and hyperkeratotic plaques. Treatment options are topical retinoids, emollients, keratolytics and topical corticosteroids with limited or no success. Oral retinoids have been shown to be successful in some cases, but recurrence is to be expected on cessation of therapy. Topical calcipotriol is an established mode of treatment for psoriasis and also reported to be effective in many hyperkeratotic skin diseases.

Main observations: A 20-year-old female patient presented with reddish-brown lesions in her axillae, groins, submammary regions and on the eyelids. Clinical and histological findings were consistent with the diagnosis of progressive symmetrical erythrokeratoderma. She had noted that her lesions did not improve with topically applied steroids and emollients. We recommended our patient to use topical calcipotriol and observed a remarkable improvement within two weeks.

Conclusion: When compared with the other treatment modalities, topical calcipotriol is a safe and effective drug with minimal side effects and it would be a good alternative.

Keywords: calcipotriol; keratoderma; progressive symmetrical erythrokeratoderma.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Progressive symmetrical erythrokeratoderma before (A) and after (B) calcipotriol therapy.
Figure 2
Figure 2
Histopathology (H&E, 120x) showing orthohyperkeratosis, irregular acanthosis and focal papillomatosis.
See this image and copyright information in PMC

References

    1. Akman A, Masse M, Mihci E, Richard G, Christiano AM, Balle BJ, Ciftcioglu MA, Alpsoy E. Progressive symmetrical erythrokeratoderma: report of a Turkish family and evaluation for loricrin and connexin gene mutations. Clin Exp Dermatol. 2008;33:582–584. - PubMed
    1. Rogers M. Erythrokeratodermas. A classification in a state of flux? Australas J Dermatol. 2005;46:127–141. - PubMed
    1. Ishida-Yamamoto A, McGrath JA, Lam H, Iizuka H, Friedman RA, Christiano AM. The molecular pathology of progressive symmetric erythrokeratoderma: a frameshift mutation in the loricrin gene and perturbations in the cornified cell envelope. Am J Hum Genet. 1997;61:581–589. - PMC - PubMed
    1. Ghorpade A, Ramanan C. Progressive symmetric erythrokeratoderma. Indian J Dermatol Venereol Leprol. 1995;61:116–117. - PubMed
    1. Arroyo MP. A young boy with symmetric hyperkeratotic plaques: progressive symmetric erythrokeratoderma (PSEK) J Drugs Dermatol. 2002;1:326–328. - PubMed

Publication types

LinkOut - more resources